XTL Biopharm Ltd

Processing Fees on ADRs to be Waived for Two Mo...


              Processing Fees on ADRs to be Waived for Two Months              

Valley Cottage, New York, August 28, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the
acquisition, development and commercialization of therapeutics for the
treatment of unmet medical needs, particularly neuropathic pain and hepatitis
C, today announced that issuances of American Depositary Receipts, or ADRs, by
the Company's depositary bank, The Bank of New York, will be processed free of
the customary charges of The Bank of New York from September 3, 2007 through
October 31, 2007.

The Bank of New York will issue ADRs representing American Depositary Shares,
or ADSs, if shareholders or their broker deposit Ordinary Shares with The Bank
of New York's Custodian, either the Tel Aviv office of Bank Hapoalim B.M., or
the London office of The Bank of New York. One ADR will represent an ownership
interest in ten of XTL's Ordinary Shares.

Interested investors should contact their brokers to discuss the waived fee and
should they have any questions, can contact The Bank of New York in either
London or New York as follows:

London                       or     New York                   
Mark Lewis                          Jason Paltrowitz           
Vice President                      Vice President             
Tel 020.7964.6089                   Tel 212.815.2077           
Fax 020.7964.6024                   Fax 212.815.3004           
[email protected]               [email protected]   

Ron Bentsur, Chief Executive Officer of XTL, commented, "We want to thank The
Bank of New York for offering shareholders this free issuance window in
conjunction with the planned cancellation of the Company's Ordinary Shares on
the Official List of the United Kingdom Listing Authority, subject to
shareholder approval at an Extraordinary General Meeting to be held on
September 25, 2007."

ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. XTL is also
developing several novel pre-clinical hepatitis C small molecule inhibitors.
 XTL also has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly traded on the
NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:
XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225
+972-8-930-4444

Cautionary Statement
Some of the statements included in this press release, particularly those
anticipating continued undisrupted trading of the Company's ADRs on NASDAQ or
the future cancellation of the Company's Ordinary Shares on the Official List
of the United Kingdom Listing Authority and similar matters, may be
forward-looking statements that involve a number of risks and uncertainties.
For those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995. Risk factors that could adversely affect our operations are
identified from time to time in our reports filed with the Securities and
Exchange Commission and the London Stock Exchange, including our annual report
on Form 20-F filed with the Securities and Exchange Commission on March 23,
2007. Any forward-looking statements set forth in this press release speak only
as of the date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at http://
www.xtlbio.com. The information in our website is not incorporated by reference
into this press release and is included as an inactive textual reference only.
This press release is for informational purposes only and is not an offer to by
or the solicitation of an offer to sell any securities.